Lys-MDA explained

Lys-MDA (Lysine-MDA, N-(L-lysinamidyl)-3,4-methylenedioxyamphetamine) is a substituted amphetamine derivative with empathogenic effects, which acts as a prodrug for MDA with a slower onset of effects and longer duration of action. Lys-MDA, along with the related derivative Lys-MDMA, are in early stage human clinical trials as potential treatments for treatment-resistant depression and post-traumatic stress disorder.New MDMA prodrugs are in the development phase at MiHKAL GmbH in Switzerland.^{[1] [2] [3] [4]}

See also

• Lisdexamfetamine
• Serdexmethylphenidate
• N-t-BOC-MDMA

Notes and References

1. Web site: MindMed announces Phase 1 study of MDMA-like substances. . Buntz B . Drug Discovery and Development . 21 September 2022 .
2. Web site: MindMed Collaborators Dose First Patient in Phase 1 Investigator-Initiated Trial of MDMA-Like Substances. . Biospace.com . 20 September 2022 .
3. Novel Safrylamine derivatives having prodrug properties. . Grill M . 17 March 2022 . Compass Pathfinder Limited . WO . 2022/053696 . . .
4. Methylenedioxymethamphetamine and Related Psychedelics and Uses Thereof . Clark S, Duncton MA . Terran Biosciences Inc . 12 January 2023 . WO . 2023/283373 . . .